You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
CANDIDA IMMUNE COMPLEX |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1352 Geisinger Epic ID: 53332 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Specimen required: |
2 mL serum; minimum 1 mL. | |
Special notes: |
Collect in red-top tube with no additives or serum gel tube. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow blood to clot for 30 minutes. Centrifuge at 3000 rpm for 10 minutes. Separate serum and freeze immediately. Ship frozen on dry ice. Submit in plastic screw-cap vial. | |
Transport temperature: |
Frozen. | |
Specimen stability: |
Room temperature: Unacceptable. Refrigerated: 7 days. Frozen: 10 weeks. | |
Rejection criteria: |
Hemolyzed specimens • Specimens received at ambient temperature • Specimens received at refrigerated temperature • Specimens outside of listed stability | |
TEST DETAILS |
||
Additional information: |
The performance characteristics of the listed assay was validated by BioAgilytix Diagnostics. The US FDA has not approved or cleared this test. The results of this assay can be used for clinical diagnosis without FDA approval. BioAgilytix Diagnostics is a CLIA certified, CAP accredited laboratory for performing high complexity assays such as this one. | |
CPT code(s): |
86332 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
|
Synonyms: |
Quest test code 95856, Cand Im Cplx
|
|
Clinical significance: |
Candida Immune Complexes which form in vivo are comprised of Candida Albicans antigen, anti-Candida IgG antibodies, and complement. The presence of these complexes is an indication of overgrowth of C. albicans in the gut. Candida overgrowth was first described by Brabander and associates in 1957. Diagnosis of the condition has been difficult due to the ubiquitous nature of Candida resulting in the existence of antibodies to it in a large percentage of the normal population. It is also difficult to isolate by culture from stool due to the overgrowth by normal intestinal flora. Symptoms of Candida intestinal overgrowth include bloating, itching, and skin rashes. Lehman and Reiss suggested that the presence of immune complexes to Candida is an objective means of diagnosing the condition. The results of Broughton and Lanson concluded that the marker for Candida immune complexes not only aid in diagnosing intestinal overgrowth, but that levels of complexes decrease during successful treatment. | |